Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29330281 | 0.87 | NPC1 (0.40) | ACKR3NPC1LMNAL3MBTL1NPSR1 | |
| SCHEMBL29477427 | 0.84 | ACKR3 (0.39) | ACKR3NPC1LMNAL3MBTL1NPSR1 | |
| SCHEMBL24363847 | 0.84 | ACKR3 (0.39) | ACKR3NPC1LMNAL3MBTL1NPSR1 | |
| SCHEMBL655760 | 0.84 | NPC1 (0.44) | ACKR3NPC1LMNAL3MBTL1NPSR1 | |
| SCHEMBL655761 | 0.84 | NPC1 (0.44) | ACKR3NPC1LMNAL3MBTL1NPSR1 | |
| SCHEMBL657227 | 0.83 | NPC1 (0.43) | ACKR3NPC1LMNAL3MBTL1NPSR1 | |
| SCHEMBL657228 | 0.83 | NPC1 (0.43) | ACKR3NPC1LMNAL3MBTL1NPSR1 | |
| SCHEMBL29330250 | 0.81 | UCHL1 (0.43) | NPC1LMNAL3MBTL1NPSR1ALDH1A1 | |
| SCHEMBL15240571 | 0.77 | UCHL1 (0.46) | NPC1LMNAL3MBTL1NPSR1ALDH1A1 | |
| SCHEMBL22012903 | 0.74 | MEN1 (0.41) | NPC1LMNAL3MBTL1NPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | ACKR3 762/4885NPC1 39/4885LMNA 1976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.